Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
13 Febbraio 2023 - 2:35PM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
that it has filed a provisional patent application for the use of
its central nervous system (CNS) homing peptides to treat
Alzheimer's disease and the onset of dementia.
Alzheimer's disease has proven to be a
progressive neurodegenerative disorder that is associated with the
destruction of higher brain structures, such as those involved in
cognition and memory function. The disease leads to deficits and
declines in memory, learning, language, and in the ability to
perform intentional and purposeful movements. Alzheimer's disease
is also accompanied by concomitant behavioral, emotional,
interpersonal, and social deterioration. Treatment of Alzheimer's
remains largely inadequate.
“There is still an unmet need for effective
methods to prevent and treat Alzheimer’s disease. Our hope is a
targeted delivery of a therapeutic agent to cells that cause
disease or are affected by a disease can improve the treatment of
Alzheimer’s and dementia,” said Eric Weisblum, Chief Executive
Officer of Silo Pharma.
Silo Pharma continues to explore the use of its
CNS homing peptides along with its study of other novel
therapeutics currently in preclinical studies.
About Silo Pharma
Silo Pharma. Inc. is a development-stage
biopharmaceutical company focused on merging traditional
therapeutics with psychedelic research for people suffering from
indications such as PTSD, Alzheimer’s disease, and other rare
neurological disorders. Silo’s mission is to identify assets to
license and fund the research which we believe will be
transformative to the well-being of patients and the healthcare
industry. For more information visit www.silopharma.com
Forward-Looking Statements
All statements other than statements of
historical fact in this announcement are forward-looking statements
that involve known and unknown risks and uncertainties and are
based on current expectations and projections about future events
and financial trends that the Company believes may affect its
financial condition, results of operations, business strategy, and
financial needs. Investors can identify these forward-looking
statements by words or phrases such as “may,” “will,” “expect,”
“anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,”
“potential,” “continue,” “is/are likely to” or other similar
expressions. The Company under takes no obligation to update
forward-looking statements to reflect subsequent occurring events
or circumstances, or changes in its expectations, except as may be
required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company’s filings with the SEC.
Contact
800-705-0120
investors@silopharma.com
Grafico Azioni Silo Pharma (NASDAQ:SILO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Silo Pharma (NASDAQ:SILO)
Storico
Da Lug 2023 a Lug 2024